NanoGroup S.A.

Warsaw Stock Exchange NNG.WA

NanoGroup S.A. Capital Expenditure for the year ending December 31, 2023: USD -19.25 K

NanoGroup S.A. Capital Expenditure is USD -19.25 K for the year ending December 31, 2023, a 89.55% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).
  • NanoGroup S.A. Capital Expenditure for the year ending December 31, 2022 was USD -184.16 K, a 80.77% change year over year.
  • NanoGroup S.A. Capital Expenditure for the year ending December 31, 2021 was USD -957.57 K, a -65.17% change year over year.
  • NanoGroup S.A. Capital Expenditure for the year ending December 31, 2020 was USD -579.73 K, a 21.87% change year over year.
  • NanoGroup S.A. Capital Expenditure for the year ending December 31, 2019 was USD -741.98 K, a 52.54% change year over year.
Key data
Date Capital Expenditure Free Cash Flow Depreciation And Amortization Deferred Income Tax
Market news
SV Wall Street
Warsaw Stock Exchange: NNG.WA

NanoGroup S.A.

CEO Mr. Przemyslaw Daniel Mazurek
IPO Date March 14, 2018
Location Poland
Headquarters Rakowiecka 36
Employees 46
Sector Healthcare
Industries
Biotechnology Pharmaceuticals
Description

NanoGroup S.A. operates as a biotechnology company. It develops and licenses early-stage biotechnology and medical projects in the areas of oncology, transplantology, and blood donations to international biotech companies and pharmaceutical companies. NanoGroup S.A was incorporated in 2016 and is based in Warsaw, Poland.

StockViz Staff

February 6, 2025

Any question? Send us an email